Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Autoimmunity. 2010 Mar;43(2):140–155. doi: 10.3109/08916930903229239

Figure 1.

Figure 1

A GpG-ODN delays the development of proteinuria in NZB/W mice. (A) Treatment schedules for two independent experiments are shown. PBS, or 50 µg of CpG-ODN, or GpG-ODN was administered intraperitoneally at the indicated time points. Numbers represent age in weeks. Colorimetric assessment of proteinuria was performed weekly beginning at 20 weeks of age and continued through 32 (B) or 40 (C) weeks of age. *p < 0.05 for the GpG-ODN group (compared to PBS-treated animals in Experiment #1) and **p < 0.05 for GpG-ODN versus CpG and for GpG-ODN versus PBS (Experiment #1), as determined by ANOVA and Dunn’s multiple comparison’s post-test. ***p < 0.05 for GpG-ODN versus PBS (Experiment 2). Representative images of PAS-stained kidney sections from Experiment 2. The top three panels are 200 × magnifications from PBS-treated (D), CpG-ODN-treated (E) and GpG-treated (F) mice. The bottom three panels are 400 × magnifications of a representative glomerulus from PBS-treated (G), CpG-ODN-treated (H), and GpG-treated (I) mice.